Why Novo Nordisk’s Weight Loss Pill Has Taken Off

The introduction of an oral GLP-1 medication, the Magovi pill by Novanordisk, offers an alternative for patients who previously hesitated due to injections, cost, or fear of needles. Over half a million prescriptions were filled in its first month. Patients like Jane Zuckerman chose the pill out of health necessity, despite initial side effects like nausea, which often subsided after a few weeks. Novanordisk aims for the pill to boost its performance and regain obesity market share from competitor Eli Lilly, whose injections have seen greater demand and are considered more effective. Novo's first-quarter sales in May will include results from the pill, with the overall Wigobi portfolio projected to grow significantly by 2031. However, Lilly recently gained FDA approval for its own oral weight loss drug, presenting direct competition. While Novo had a three-month head start, analysts believe Lilly's pill could capture substantial market share, particularly as it has fewer restrictions (Novo users must wait 30 minutes before eating or drinking). The Magovi pill's early success is also attributed to its relatively low price point and a subscription model, making it a more accessible option for patients prioritizing their health.